MX388643B - Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos - Google Patents

Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos

Info

Publication number
MX388643B
MX388643B MX2019011904A MX2019011904A MX388643B MX 388643 B MX388643 B MX 388643B MX 2019011904 A MX2019011904 A MX 2019011904A MX 2019011904 A MX2019011904 A MX 2019011904A MX 388643 B MX388643 B MX 388643B
Authority
MX
Mexico
Prior art keywords
agonist
kor
pharmaceutical composition
composition containing
mor
Prior art date
Application number
MX2019011904A
Other languages
English (en)
Other versions
MX2019011904A (es
Inventor
Changyong Yang
Guoqing Cao
Lianshan Zhang
Zhuolu Niu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019011904A publication Critical patent/MX2019011904A/es
Publication of MX388643B publication Critical patent/MX388643B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan usos de la combinación de un agonista del receptor de opioides µ (MOR) y un agonista del receptor de opioides ? ( KO R) e n l a p r e p a r a c i ó n d e f á rma c o s p a r a a l i v i a r y / o t r a t a r e l d o l o r. El agonista de MOR se selecciona del compuesto representado en la fórmula ( I ) o un tautómero, mesómero, racemato, enant iómero o diaestereómero de él , o una mezcla de el los, o una sal de el los aceptable farmacéut icamente. También se proporciona una composición farmacéut ica que cont iene el agonista de MOR y el agonista de KOR.
MX2019011904A 2017-04-14 2018-04-13 Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos MX388643B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710242435 2017-04-14
PCT/CN2018/082912 WO2018188641A1 (zh) 2017-04-14 2018-04-13 一种mor激动剂与kor激动剂的药物组合物及其用途

Publications (2)

Publication Number Publication Date
MX2019011904A MX2019011904A (es) 2019-11-25
MX388643B true MX388643B (es) 2025-03-20

Family

ID=63792284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011904A MX388643B (es) 2017-04-14 2018-04-13 Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos

Country Status (11)

Country Link
US (1) US20200054594A1 (es)
EP (1) EP3610874A4 (es)
JP (1) JP2020516591A (es)
KR (1) KR20190133047A (es)
CN (1) CN109982699A (es)
AU (1) AU2018251118A1 (es)
BR (1) BR112019020691A2 (es)
CA (1) CA3058272A1 (es)
MX (1) MX388643B (es)
TW (1) TW201836606A (es)
WO (1) WO2018188641A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005660A (es) * 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Ltd Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.
CN111836807A (zh) * 2018-04-28 2020-10-27 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN112334465B (zh) * 2019-01-17 2024-06-11 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2021026492A1 (en) * 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
CN112789276B (zh) * 2019-08-14 2024-07-30 上海海雁医药科技有限公司 镇痛化合物、其制法与医药上的用途
CN112552374B (zh) * 2019-09-10 2024-06-04 西藏海思科制药有限公司 一种肽酰胺类化合物及其中间体的制备方法
KR102847070B1 (ko) 2020-01-17 2025-08-14 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
CN114269751B (zh) * 2020-01-17 2024-04-16 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
WO2022185952A1 (ja) * 2021-03-04 2022-09-09 ソシウム株式会社 ガン治療薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100648133B1 (ko) 2005-04-25 2006-11-23 일동제약주식회사 펩티드 데포르밀라제 저해제로서 신규의 히드록사믹 산유도체 및 그 제조방법
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
DK2064228T3 (da) * 2006-11-10 2012-12-10 Cara Therapeutics Inc Syntetiske peptidamider
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
KR101991326B1 (ko) * 2011-03-23 2019-06-20 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
WO2013132408A1 (en) * 2012-03-04 2013-09-12 Jeffries Adam Data systems processing
WO2015065867A2 (en) 2013-10-28 2015-05-07 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US20180028594A1 (en) 2014-11-05 2018-02-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for hard tissue pain
WO2016187537A1 (en) * 2015-05-21 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Multifunctional opioid receptor ligands and methods of treating pain
KR102703513B1 (ko) * 2015-10-15 2024-09-06 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 옥사 스파이로 유도체, 이의 제조방법, 및 의약에서 이의 응용
CN107098871B (zh) 2016-02-23 2021-07-02 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
BR112019021447A2 (pt) * 2017-04-14 2020-05-05 Jiangsu Hengrui Medicine Co sal fumarato, forma cristalina i do referido sal, métodos para preparação dos mesmos, composição farmacêutica compreendendo o sal e a forma cristalina i e uso do sal fumarato, da forma cristalina i e da composição farmacêutica
MX2020005660A (es) * 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Ltd Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.

Also Published As

Publication number Publication date
MX2019011904A (es) 2019-11-25
BR112019020691A2 (pt) 2020-05-12
US20200054594A1 (en) 2020-02-20
EP3610874A4 (en) 2021-01-06
AU2018251118A1 (en) 2019-10-17
TW201836606A (zh) 2018-10-16
WO2018188641A1 (zh) 2018-10-18
KR20190133047A (ko) 2019-11-29
JP2020516591A (ja) 2020-06-11
EP3610874A1 (en) 2020-02-19
CN109982699A (zh) 2019-07-05
CA3058272A1 (en) 2018-10-18
AU2018251118A8 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX388643B (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
ZA202007671B (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12017501570A1 (en) Bicyclic ketone sulfonamide compounds
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
MX2020008498A (es) Derivados de sobetirome.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2016014946A (es) Derivados de carboxamida.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
PH12019550154B1 (en) Azetidine derivative
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MY190027A (en) P38 map kinase inhibiting indanyl urea compounds